PRIMARY STUDY

Neuroprotection with the cannabigerol quinone derivative VCE-003.2 and its analogs CBGA-Q and CBGA-Q-Salt in Parkinson's disease using 6-hydroxydopamine-lesioned mice

Key Findings:  CBG and various analogue (i.e. VCE-003.2, cannabigerolic acid quinone (CBGA-Q) and its sodium salt CBGA-Q-Salt) have shown neuroprotective properties (likely via modulation of PPAR-γ) in inflammatory animal models of Parkinson's disease.